Sei sulla pagina 1di 47

2011–2015 Global Diabetes Drugs Market

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF. technavio insights
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
2011–2015 Global Diabetes Drugs Market

CONTENTS

01. Executive Summary ..............................................1

02. Introduction ...........................................................2

03. Market Coverage .................................................4


Market Overview ..................................................................................................... 4

Key Offerings ............................................................................................................ 4

04. Market Landscape ................................................5


04.1 Global Diabetes Drugs Market ........................................... 5
Market Size ................................................................................................................ 5

04.2 Available Drug Classes for Diabetes .................................. 7

04.3 Share of DPP4 Drugs in BRIC Countries in 2011 ................. 8


Brazil ........................................................................................................................... 8

India ........................................................................................................................... 8

Russia ......................................................................................................................... 9

China ......................................................................................................................... 9

Consolidated Share of DPP4 Drugs in BRIC Countries in 2011 ...................... 10

04.4 Share of DPP4 Drugs in European Countries in


2011 ....................................................................................... 11
France...................................................................................................................... 11

Germany ................................................................................................................. 11

Italy ........................................................................................................................... 12

Spain ........................................................................................................................ 12

UK.............................................................................................................................. 13

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
2011–2015 Global Diabetes Drugs Market

Consolidated Share of DPP4 Drugs in European Countries in 2011 ............. 13

04.5 Five Forces Analysis ............................................................. 14

05. Geographical Segmentation .............................15

06. Rate of Incidence and Prevalence ...................16

07. Vendor Landscape .............................................17

08. Buying Criteria .....................................................19

09. Market Growth Drivers ........................................20

10. Drivers and their Impact .....................................22

11. Market Challenges .............................................23

12. Impact of Drivers and Challenges .....................25

13. Market Trends ......................................................26

14. Key Vendor Analysis ...........................................28


14.1 Novo Nordisk A/S ................................................................. 28
Business Overview ................................................................................................. 28

SWOT Analysis ......................................................................................................... 30

14.2 Merck & Co., Inc. ................................................................ 31


Business Overview ................................................................................................. 31

SWOT Analysis ......................................................................................................... 33

14.3 Bristol-Myers Squibb Co. ..................................................... 34


Business Overview ................................................................................................. 34

SWOT Analysis ......................................................................................................... 36

14.4 Sanofi S.A. ............................................................................. 37


Business Overview ................................................................................................. 37

SWOT Analysis ......................................................................................................... 39

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
2011–2015 Global Diabetes Drugs Market

15. Other Reports in this Series .................................41

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
2011–2015 Global Diabetes Drugs Market

EXHIBITS

Exhibit 1: Global Diabetes Drugs Market 2011–2015 (US$


million) ....................................................................................5

Exhibit 2: Global Diabetes Drugs Market by Route of


Administration .......................................................................6

Exhibit 3: Global Diabetes Drugs Market by Geographical


Segmentation 2011 ............................................................15

Exhibit 4: Global Diabetes Drugs Market by Vendor


Segmentation 2011 ............................................................18

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 1

01. Executive Summary


 2011: US$28,000 million
Market Size
 2015: US$40,550 million

Growth Rate  9.7 percent CAGR

 The Americas: 42 percent


Key Geographies  EMEA: 32 percent
 APAC: 26 percent

 Hospitals
Key Customer
 Patients
Segments
 Diabetes Clinics

 Increase in Diabetic Population


 Increase in Aging Population
Drivers
 Increase in Health Insurances
 Introduction of Novel Drug Classes

 Increasing Use of Complementary and Alternative Medicine


(CAM)
Challenges  Stringent Drug Approval Policies
 Increasing Generic Competition
 Lack of Awareness

 Increasing Awareness and Education


 Mergers and Acquisitions
Trends
 Maintenance of Healthy Lifestyles
 Emergence of Combination Therapies

 Convenient Mode of Delivery for Insulin


Key Customer Needs  Low Cost
 Safety and Efficacy

 Eli Lilly & Co.


 Merck & Co., Inc.
Key Vendors
 Novo Nordisk A/S
 Sanofi S.A.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 2

02. Introduction
Diabetes is a condition in which the human body is unable to properly use and store glucose.
Most of the food we eat is broken down into glucose. Once the food is digested, glucose passes
into the bloodstream and is used by cells for growth and energy. The presence of insulin is
required to get glucose into cells. People suffering from diabetes produce either little or no
insulin, or their cells do not respond appropriately to the insulin that is produced. This causes
glucose build-up in the blood, leading to diabetes. The burden of diabetes is increasing globally,
particularly in developing countries. According to the International Diabetes Federation (IDF), in
2011, 366 million people across the world were suffering from diabetes. In 2011, diabetes caused
almost 4.6 million deaths worldwide. Eighty percent of diabetic patients live in low and middle-
income countries. Diabetes is no longer a disease of only developed countries. The disease is
more prevalent in developing countries such as China, India, Indonesia, Bangladesh, and
Philippines.

The Global Diabetes Drugs market was valued at US$28,000 million in 2011. Over the years, the
market has experienced remarkable growth. This growth is mainly driven by the increasing
occurrence of diabetes globally. The prevalence of diabetes is increasing because of changing
food habits and lifestyles. In 2011, most of the growth in the Global Diabetes Drugs market was
from the Americas and the Europe, Middle East, and Africa (EMEA) region, which together
accounted for 70–75 percent of the market. There is a vast opportunity for vendors in this market
to expand into the Asia Pacific (APAC) countries such as India, China, and Japan. This is
because of the increasing patient population in these countries. The Global Diabetes Drugs
market is expected to grow at a CAGR of 9.7 percent during the period 2011–2015.

The growth of the Global Diabetes Drugs market is driven by several factors. One of the key
drivers is the increase in the diabetic population. Across the globe, the prevalence of diabetes is
growing at a significant pace. Increasing urbanization coupled with sedentary lifestyles has led
to the increase in the diabetic population. The prevalence of diabetes is not only increasing in
developed nations but also in low and middle-income countries, particularly in India, China, and
Japan. Moreover, an increase in the aging population and the introduction of novel classes of
drugs are driving the growth of the market.

Despite the growth drivers, the Global Diabetes Drugs market faces some challenges. One of
the key challenges is the increasing use of complementary and alternative medicine (CAM). As
CAMs are cheaper alternatives to conventional medical care, their use is gaining prominence
across the world. The increasing use of CAM therapies to treat diabetes poses a significant

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 3
challenge to the growth of the Global Diabetes Drugs market. Stringent drug approval policy
along with increasing generic competition also poses a strong challenge to the growth of the
market.

The Global Diabetes Drugs market is witnessing several trends that will impact its growth during
the forecast period. The market is witnessing increasing awareness and education regarding the
importance of healthy lifestyles. The market is also witnessing various strategic alliances and
acquisitions among companies. Overall, the Global Diabetes Drugs market is expected to grow
at a significant pace during the forecast period.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 4

03. Market Coverage


Market Overview
This report covers the present scenario and the growth prospects of the Global Diabetes Drugs
market for the period 2011–2015. To calculate the market size, the report considers the revenue
generated from the sales of diabetes drugs. It also presents the vendor landscape and a
corresponding detailed analysis of the top four vendors in the Global Diabetes Drugs market. In
addition, the report discusses the major drivers that influence the growth of the market. It also
outlines the challenges faced by the vendors and the market at large, as well as the key trends
emerging in the market.

Key Offerings
Some of the key products offered by the major vendors in the Global Diabetes Drugs market are
listed below:

Company
Key Products

Novo Nordisk A/S Levemir, NovoRapid, NovoMix, Insulatard, Actrapid, Mixtard 30,
Victoza, NovoNorm, PrandiMet

Sanofi S.A. Lantus, Apidra, Insuman, Amaryl/Amarel

Merck & Co., Inc. Janumet, Janumet Xr, Januvia, Juvisync

Eli Lilly & Co. Humalog, Humulin

Bristol-Myers Squibb Co. Onglyza, Kombiglyze

GlaxoSmithKline plc Avandia

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 5

04. Market Landscape


04.1 Global Diabetes Drugs Market

Market Size
The Global Diabetes Drugs market was valued at US$28,000 million in 2011 and it is expected to
reach US$40,550 million by 2015, growing at a CAGR of 9.7 percent.

Exhibit 1: Global Diabetes Drugs Market 2011–2015 (US$ million)

Source: TechNavio Analysis

Some of the top selling drugs in 2011 were Novolog from Novo Nordisk A/S, Januvia from Merck
& Co., Inc., Humalog from Eli Lilly & Co, and the long-acting insulin analog Lantus from Sanofi S.A.
The main segments of the market are Insulin and Oral Anti-diabetes Drugs. Metformin, which
belongs to the biguanide class of drugs, remains the first choice among the oral anti-diabetes
drugs. New forms of combination therapies such as glucagon-like peptide (GLP) agonists,
sodium-dependent glucose (co) transporter (SGLT) inhibitors, and Dipeptidyl peptidase-4 (DPP4)
inhibitors are expected to become strong competitors in the near future. In Europe, it is
expected that long-acting insulins will have a large market during the forecast period.
Furthermore, in the coming years, new therapeutic classes of drugs are expected to become
major contributors. Strict guidelines of the European Medicines Agency and the US Food and
Drug Administration regarding safety issues are expected to have a high impact in the market in

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 6
the future. In the next few years, Glucagon-like peptide-1 (GLP-1) receptor agonists and new
combination therapies are expected to fuel the growth of the market in Europe, while Metformin
is expected to continue as a strong competing product. The Insulin segment is dominated by
modern insulins and analogs. Long-acting insulins are expected to have a significant market
share in the future. New therapeutic classes of drugs are expected to become major
contributors to the Oral Anti-diabetes Drugs segment during the forecast period.

Exhibit 2: Global Diabetes Drugs Market by Route of Administration

Source: TechNavio Analysis

In 2011, the Global Diabetes Drugs market was valued at US$28,000 million, with oral drugs
constituting around 35 percent and injectables contributing almost 50 percent.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 7
04.2 Available Drug Classes for Diabetes

Insulins Insulin Biguanides Sulfonylureas Meglitinides DPP4 GLP-1


Sensitizers Inhibitors Analogs

Humalog Avandia Glucophage Amaryl Prandin Alogliptin Lixisenatide

Novolog Actos Glumetza Glucotrol Starlix Dutogliptin Byetta

Humulin Glucophage XR Glucotrol XL Galvus LY2189265

Lantus DiaBeta Januvia Syncria

Levemir Glynase PreTab Ondero Tapsoglutide

Novolin Micronase Onglyza Victoza

Afresa Eucreas

Apidra Janumet

Tradjenta

Kombiglyze

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 8
04.3 Share of DPP4 Drugs in BRIC Countries in 2011

Brazil

Source: TechNavio Analysis

India

Source: TechNavio Analysis

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 9
Russia

Source: TechNavio Analysis

China

Source: TechNavio Analysis

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 10
Consolidated Share of DPP4 Drugs in BRIC Countries in 2011

Source: TechNavio Analysis

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 11
04.4 Share of DPP4 Drugs in European Countries in 2011

France

Source: TechNavio Analysis

Germany

Source: TechNavio Analysis

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 12
Italy

Source: TechNavio Analysis

Spain

Source: TechNavio Analysis

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 13
UK

Source: TechNavio Analysis

Consolidated Share of DPP4 Drugs in European Countries in 2011

Source: TechNavio Analysis

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 14
04.5 Five Forces Analysis

Bargaining Power of
Suppliers
(Medium)
Many suppliers in the market
provide a diverse range of
raw materials for the
development and
manufacture of diabetes
drugs

Threat of Substitutes Threat of Rivalry Bargaining Power of


(Low) (High) Buyers
Low cost complementary Competition among the (Medium)
and alternative medicines existing vendors is quite high
as the market is fragmented. Although many products are
could act as substitutes for available in the market,
Moreover, vendors are
diabetes drugs. However, introducing novel classes of safety and efficacy issues
they are not always safe drugs to remain competitive limit the bargaining power of
and effective in the market buyers

Threat of New Entrants


(High)
The probability of new
vendors entering the
Diabetes Drugs market is
high as it is the most
lucrative segment of the
Pharmaceutical industry.
Moreover, generic players
are likely to enter the
market because of the
approaching patent expiry
of many of the drugs

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 15

05. Geographical Segmentation


The Americas leads the Global Diabetes Drugs market. In 2011, it accounted for 42 percent of
the market, which equates to US$11,760 million. The Americas was followed by the EMEA region,
with a market share of 32 percent, which equates to US$8,960 million. The APAC region
accounted for the remaining 26 percent of the market, which equates to US$7,280 million. In the
Americas, the US is the largest revenue contributor to this market. The major contributors in the
EMEA region are the UK, France, Italy, and Germany. In the APAC region, Japan, India, and
China are the major revenue contributors. Emerging countries such as China, Japan, and India
present excellent opportunities for the Diabetes Drugs market in the APAC region because of
the increase in the diabetic population and increasing awareness about the disease in these
countries. Although the APAC region currently has the lowest market share, its growth rate is
higher than the Americas and the EMEA region. With the continuous economic growth in the
APAC region, especially in India and China, the contribution of the US market is expected to
drop by 3–5 percent during the forecast period.

Exhibit 3: Global Diabetes Drugs Market by Geographical Segmentation 2011

Source: TechNavio Analysis

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 16

06. Rate of Incidence and Prevalence


In 2011, the estimated worldwide number of people with diabetes was 366 million. In 2011,
diabetes caused 4.6 million deaths. In 2011, the International Diabetes Federation (IDF)
estimated that China, India, the US, Russia, and Brazil are the five countries with the largest
numbers of people with diabetes. Low and middle-income countries face the greatest burden
of diabetes. Almost 80 percent of diabetes deaths occur in low and middle-income countries. In
2011, 2.9 million people were diagnosed with diabetes in the UK. According to the World Health
Organization (WHO), about 60 million people in Europe have diabetes. In Europe, almost 10.3
percent of men and 9.6 percent of women aged 25 years and over have diabetes.

In 2011, the Centers for Disease Control and Prevention (CDC) estimated that almost 26 million
Americans have diabetes. According to the National Diabetes Fact Sheet for 2011, Diabetes
affects 8.3 percent of Americans of all ages and 11.3 percent of adults aged 20 and older. An
estimated 1.9 million Americans were diagnosed with diabetes in 2010.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 17

07. Vendor Landscape


Vendors in the Global Diabetes market are either developing novel classes of drugs or acquiring
other manufacturers to increase their share in the market. The market is becoming increasingly
competitive because of the increase in the diabetic population. The incidence of diabetes is
increasing at a significant pace around the world. This presents a huge opportunity to the
market players. The Global Diabetes Drugs market is quite dynamic with active R&D leading to
newer drug classes. However, the FDA has increased the regulatory surveillance over diabetes
drugs to avoid any associated risks. The stringent approval policies are in turn delaying the
launch of new drugs in the market.

The Global Diabetes Drugs market is very competitive and it is dominated by well-known
vendors such as Novo Nordisk, Sanofi, Eli Lilly, GlaxoSmithKline plc, and Merck. Leading vendors
that develop diabetes drugs are from the Americas and the EMEA region.

Some of the key vendors in the market are listed below:

Company Category/Description

Novo Nordisk A/S A global healthcare company. The company has one of the
broadest diabetes product portfolios in the industry. It is
engaged in the discovery, development, manufacture, and
marketing of pharmaceutical products.

Sanofi S.A. A global pharmaceutical company that discovers, develops,


and distributes therapeutic solutions. It develops prescription
drugs, vaccines, generics, and consumer healthcare products.

Eli Lilly & Co. Discovers, develops, manufactures, and sells pharmaceutical
products.

GlaxoSmithKline plc A multinational pharmaceutical, biologics, vaccines, and


consumer healthcare company mainly engaged in the
discovery, development, manufacture, and marketing of
pharmaceutical products, including vaccines.

Merck & Co., Inc. A global healthcare company that delivers healthcare solutions
through its prescription medicines, vaccines, biologic therapies,
animal health products, and consumer care products.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 18
Exhibit 4: Global Diabetes Drugs Market by Vendor Segmentation 2011

Source: TechNavio Analysis

The leading vendor in the Global Diabetes Drugs market is Novo Nordisk. In 2011, it held a share
of around 34 percent of the Global Diabetes Drugs market. Novo Nordisk was followed by
Sanofi, with a market share of 23 percent. In 2011, Merck accounted for 17 percent of the
Global Diabetes Drugs market. Eli Lilly accounted for around 13 percent of the market. The
remaining 13 percent of the market was fragmented between other major vendors such as
Bristol-Myers Squibb Co., GlaxoSmithKline, Amylin Pharmaceuticals Inc., and Novartis AG.

About three quarters of Novo Nordisk's sales come from diabetes products. Insulin analogs form
the largest part of its sales. Novo Nordisk's products include Levemir, NovoRapid, and
NovoMix. In 2011, the sales of its insulin analogs grew more than 20 per cent compared with
2010. Novo Nordisk is a key player in the Insulin market, accounting for almost a 50 percent share
of the market.

Sanofi is fairly strong in emerging markets, particularly in the APAC region. Lantus, one of the
leading products of the company, registered total sales of US$5,451 million in 2011, constituting
almost 80 percent of the total diabetes drugs sold by the company. However, Lantus will go off
patent in 2014. Sanofi acquired Genzyme Corp. in 2011. It is expected that the company will
make up for the loss of sales due to patent expiry of Lantus through the acquisition of Genzyme
and sales of growth products. Growth products, along with the product portfolio of Genzyme,
are expected to account for 80 percent of the sales of the company by 2015.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 19

08. Buying Criteria


Parameters Details End-users Significance Attached

Convenient Delivery of insulin with Hospitals Low High


Mode of focus on increasing 1 2 3 4 5
Delivery for patient convenience,
Patients
Insulin causing less skin irritation Low High
and pain 1 2 3 4 5
Diabetes Clinics Low High
1 2 3 4 5
Cost The price at which Hospitals Low High
diabetes drugs are 1 2 3 4 5
available in the market
Patients Low High
1 2 3 4 5
Diabetes Clinics Low High
1 2 3 4 5
Safety and The ability of the diabetes Hospitals Low High
Efficacy drugs to effectively treat 1 2 3 4 5
the disease without
Patients
causing adverse effects Low High
1 2 3 4 5
Diabetes Clinics Low High
1 2 3 4 5

Key
The impact of the buying criteria is graded based on the intensity and duration of the impact on
the current market landscape. The magnitude of the impact has been categorized as
described below:

 Low – Negligible or no impact on the market landscape


 Medium – Medium-level impact on the market
 High – Very high impact with radical influence on the growth of the market

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 20

09. Market Growth Drivers


The worldwide diabetic population has been continuously increasing over the years. Various
factors responsible for diabetes include smoking, alcohol, obesity, and hypertension. The
increasing prevalence of diabetes and the high market potential of diabetes drugs have
encouraged various companies to explore the Diabetics Drugs market. An increase in the
diabetic population and increase in the aging population are among the key drivers of the
Global Diabetes Drugs market.

Some of the key drivers of the Global Diabetes Drugs market are discussed below:

 Increase in Diabetic Population


 Increase in Aging Population
 Increase in Health Insurances
 Introduction of Novel Drug Classes

Increase in Diabetic Population


The prevalence of diabetes is growing at a significant pace. Increasing urbanization has caused
a significant shift from active lifestyles to more sedentary lifestyles, where consumption of sugar
rich foods is more. Sedentary lifestyle coupled with the use of meat, dairy, and processed foods
increase the chances of developing diabetes. Currently there are around 366 million people
diagnosed with diabetes globally. Low and middle-income countries face the greatest burden
of diabetes. Almost 80 percent of diabetes deaths occur in low and middle-income countries.
China and India are currently the biggest Diabetes markets. 70 percent of the diabetes cases
are currently found in low and middle-income countries, with prevalence ranging from 10.2
percent in the western Pacific to 3.8 percent in Africa. In 2010, a population-based national
study revealed that 92.4 million adults in China are diabetic. This is providing lucrative untapped
opportunities for pharmaceutical companies. The increase in the prevalence of diabetes in the
growing economies of China and India will prove to be a major driving force for the growth of
Global Diabetes Drugs market. The worldwide increase in the number of diabetes patients is
boosting the growth of the Diabetes Drugs market.

Increase in Aging Population


The world’s population is growing older. Aging is a major risk factor for the development of
diabetes. Diabetes is a common problem in older adults. Approximately 20 percent of the
population is afflicted with diabetes by the age of 65. The prevalence of diabetes is expected to
rise sharply in the future because of the increase in the aging population. Older people are
more likely to develop diabetes. Approximately 12.6 percent of the current US population is

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 21
aged 65 years and older. Population aging is occurring in both developed and developing
countries. The UN Population Division has projected that the number of people over age 65 will
increase many times over in the near future. The increase in the aging population is expected to
have a positive effect on the growth of the Global Diabetes Drugs market.

Increase in Health Insurances


Earlier, insurance providers used to deny coverage to people with pre-existing chronic
conditions, including diabetes. In recent years, encouraging reimbursement policies are being
offered by insurance providers. The introduction of diabetes insurance policies is helping the
market to grow. The increasing economic power of China and India, along with improvements
in health insurance coverage, has resulted in increased access to healthcare and the ability to
afford branded drugs. Governments all over the world are taking huge initiatives to provide
better access to the diagnostic and therapeutic options available for diabetes.

Introduction of Novel Drug Classes


It is anticipated that advanced therapies and innovative drug delivery techniques will have a
significant impact on the Global Diabetes Drugs market by 2015. The emergence of newer
classes of drugs against diabetes is changing the landscape of the Global Diabetes Drugs
market. Increasing knowledge about the pathology of diabetes and the discovery of new
technologies are expected to support the introduction of improved drugs to treat the disease.
The newer and much improved long-acting Glucagon-like peptide-1 (GLP-1) analogs are likely
to gain the same significance as insulins in the near future. In coming years, many novel
emerging drug classes will be available for the treatment of diabetes because of the rapid
advances in technology. Hence, the introduction of newer and better drugs is expected to drive
the growth of the market.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 22

10. Drivers and their Impact


Impact on End-user Category
Drivers
Hospitals Patients Diabetes Clinics

Increase in Diabetic Low High Low High Low High


Population 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Increase in Aging Low High Low High Low High
Population 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Increase in Health Low High Low High Low High
Insurances 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Introduction of Novel Drug Low High Low High Low High
Classes 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5

Impact on Geography
Drivers
Americas EMEA APAC

Increase in Diabetic Low High Low High Low High


Population 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Increase in Aging Low High Low High Low High
Population 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Increase in Health Low High Low High Low High
Insurances 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Introduction of Novel Drug Low High Low High Low High
Classes 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5

Key
The impact of the drivers is graded based on the intensity and duration of the impact on the
current market landscape. The magnitude of the impact has been categorized as described
below:

 Low – Negligible or no impact on the market landscape


 Medium – Medium-level impact on the market
 High – Very high impact with radical influence on the growth of the market

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 23

11. Market Challenges


Despite the significant growth, the Global Diabetes Drugs market faces some serious growth
inhibitors. One of the main challenges is the increasing use of CAM. CAM is one of the
alternative treatments considered by diabetes patients. Stringent drug approval policy is
another major factor hampering the growth of the Global Diabetes Drugs market.

Some of the key challenges in the Global Diabetes Drugs market are discussed below:

 Increasing Use of Complementary and Alternative Medicine (CAM)


 Stringent Drug Approval Policies
 Increasing Generic Competition
 Lack of Awareness

Increasing Use of Complementary and Alternative Medicine (CAM)


CAMs include products and practices that people choose as adjuncts or alternatives to
scientific medical approaches. More than 80 percent of people in developing nations can
barely afford the most basic medical procedures, drugs, and vaccines. Even in the industrial
nations, large proportions of people opt for CAM. As CAMs are cheaper alternatives to
conventional medical care, their use is gaining prominence across the world. The increasing use
of CAM to treat diabetes can pose a significant challenge to the growth of the Global Diabetes
Drugs market.

Stringent Drug Approval Policies


Drug development is a complex, lengthy, and expensive process. Stringent drug approval
policies cause dramatic cost increase to the companies developing new drugs. Moreover, these
stringent policies compel lengthier clinical trials, causing more operational pressures to
companies. This often results in the delayed launch of new drugs and increased drug
development costs. Such stringent drug approval policies will hamper the introduction of newer
and more advanced anti-diabetes drug classes in the market.

Increasing Generic Competition


Generic drugs are often introduced once the patent on the branded drugs expires. There has
been a significant increase in the generic competition because of the patent expiry of major
diabetes drugs. In the emerging markets of Asia, Africa, and South America, the increasing
generic competition is leading to downward pricing pressures. This is posing a major challenge
to the market expansion. In the near future, the existing anti-diabetic therapies will become

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 24
exposed to generic competition, posing a significant challenge to the Global Diabetes Drugs
market.

Lack of Awareness
Diabetes is one of the most challenging health problems. Across the globe, governments agree
that diabetes is a rising threat. However, many people are not educated about the disease and
this leads to neglect of possible causes and symptoms. The majority of the global population
lacks awareness about diabetes, especially about its types, mode of acquiring it, prevention,
and management. The lack of awareness about the various diagnostic and treatment options
available for diabetes poses a major challenge to the market.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 25

12. Impact of Drivers and Challenges


Impact of the top four drivers and challenges on the Global Diabetes Drugs market is illustrated
below:

Key
The impact of the drivers and challenges is graded based on the intensity and duration of the
impact on the current market landscape. The magnitude of the impact has been categorized
as described below:

 Low – Negligible or no impact on the market landscape


 Medium – Medium-level impact on the market
 Moderately High – Significant impact on the growth of the market
 High – Very high impact with radical influence on the growth of the market

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 26

13. Market Trends


Governments and various non-government agencies are conducting awareness programs to
increase awareness about diabetes. It is one of the major trends witnessed by the Global
Diabetes Drugs market. The market is also witnessing an increase in strategic alliances between
various companies to increase their capability, develop improved diabetes drugs, and increase
their market presence.

Some of the key trends in the Global Diabetes Drugs market are discussed below:

 Increasing Awareness and Education


 Mergers and Acquisitions
 Maintenance of Healthy Lifestyles
 Emergence of Combination Therapies

Increasing Awareness and Education


In the US, more than one-tenth of diabetes patients are unaware of their disease. Campaigns
are being organized to create awareness about diabetes among the US population. The
American Diabetes Association (ADA) has been organizing programs and circulating magazines
about diabetes in the US. The Centers for Disease Control and Prevention is also taking initiatives
to spread awareness about diabetes. Some awareness programs sponsored by vendors even
offer free tests to patients and inform them about the condition. The number of such campaigns
is increasing worldwide, and the awareness level among the worldwide population is set to
increase in the near future. Market growth is expected to be fueled by improved education
regarding the importance of blood glucose management.

Mergers and Acquisitions


In recent years, the Global Diabetes Drugs market has been witnessing many mergers and
acquisitions. Several pharmaceutical companies are seeking strategic partnerships and
alliances with companies that boast promising marketed or pipeline drugs. For instance, in 2010,
OSI Pharmaceuticals, Inc. acquired Astellas Pharma Inc., and Sanofi acquired Ascendis Pharma
A/S. In order to compete in the market, smaller companies are using new strategies involving
mergers, acquisitions, licensing deals, and co-operation.

Maintenance of Healthy Lifestyles


There has been a significant increase in the initiatives taken by diabetic patients to maintain a
healthy lifestyle. People are refraining from smoking and alcohol in order to prevent ailments
such as diabetes. Furthermore, daily exercise and use of balanced diet have become more

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 27
common now compared to earlier years. This trend of maintenance of healthy lifestyles would
greatly affect the growth of the Global Diabetes Drugs market in future.

Emergence of Combination Therapies


In most studies of previously insulin-treated patients, glycemic control was better with insulin
combination therapy when compared with insulin alone. Combination regimens limit the use of
insulin injections. In order to treat hyperglycemia as well as other risk factors associated with
diabetes, simple insulin combination regimens are widely used. Weight gain is quite proportional
to the number of insulin injections used. Weight gain due to insulin injections can be
counteracted by inclusion of Metformin in the treatment regimen. Combining drugs into single-
pill formulations has proved to be a valuable life-cycle management tool for some companies.
For example, GSK has combined Avandia with Metformin to make Avandamet.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 28

14. Key Vendor Analysis


14.1 Novo Nordisk A/S

Business Overview
Novo Nordisk A/S is a global healthcare company. It is one of the world leaders in diabetes care.
The company has one of the broadest diabetes product portfolios in the Healthcare industry.
The company also possesses an advanced portfolio of modern insulins as well as human once-
daily GLP-1 analogs. In addition, Novo Nordisk has a leading position in hemophilia care, growth
hormone therapy, and hormone replacement therapy. The company has its headquarters in
Denmark. Novo Nordisk employs more than 32,000 people in 75 countries and markets its
products in more than 190 countries. The company generated revenue of US$12.4 billion in
FY2011.

Novo Nordisk is engaged in the discovery, development, manufacturing, and marketing of


pharmaceutical products. It has two business segments: Diabetes Care and
Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1, other protein-related
products and projects (such as glucagon and protein-related delivery systems), and obesity and
oral anti-diabetic drugs. The Biopharmaceuticals segment covers the therapy areas of
hemophilia, growth hormone therapy, hormone replacement therapy, and inflammation.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 29

Company Details Description

Product Portfolio  Levemir, NovoRapid, NovoMix, Insulatard, Actrapid, Mixtard


30, Victoza, NovoNorm, PrandiMet

Recent Product Launches  In 2011, Levemir was approved for pediatric use in Europe.
 In 2011, Levemir was approved for the treatment of
gestational diabetes in Europe.
 In 2011, Levemir was approved as an add-on therapy to
Victoza for type 2 patients in Europe.
 In 2011, FlexTouch, the newest innovation in prefilled
devices, was approved in Europe and introduced in the UK.
 In 2011, the company launched a new prefilled device,
Norditropin FlexPro, in Australia.
 In 2010, Vagifem was launched in North America and
Europe.
 In January 2010, Victoza obtained FDA approval. The
product had already been available in some European
countries and Japan since 2009.

Key Highlights  In 2011, Phase 3 trial was initiated for insulin


Degludec/Liraglutide fixed-dose combination.
 In 2011, Novo Nordisk filed for regulatory approval of
recombinant factor XIII in the US and Europe.
 In December 2011, Novo Nordisk filed for regulatory
approval of the ultra-long-acting insulin Degludec in Japan.
 In September 2011, Novo Nordisk filed for regulatory
approval of ultra-long-acting insulins Degludec and
DegludecPlus in the US.
 In September 2011, Novo Nordisk filed for regulatory
approval of the ultra-long-acting insulins Degludec and
DegludecPlus in Europe.

Key Partnerships  In November 2011, Maersk Oil and Novo Nordisk launched a
new partnership to tackle diabetes in Qatar.
 In September 2010, the European Foundation for the Study
of Diabetes (EFSD), the Juvenile Diabetes Research
Foundation (JDRF), and Novo Nordisk renewed partnership
for type 1 diabetes research in Europe.
 In May 2010, Novo Nordisk partnered with the international
scientific community for Victoza cardiovascular outcomes
trials.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 30
SWOT Analysis

Strengths Weaknesses
• Novo Nordisk has the broadest portfolio • The company suffered a negative
of diabetes products in the Healthcare brand image because of its failure to
industry provide information about the side
effects of Victoza
•The company holds the largest share in
the Global Diabetes Drugs market •Past legal actions have created a
negative image for the company
•The company has a strong presence in
the APAC region, particularly in China, •The company has many pending
which has one of the largest diabetes litigation suits
populations

•The company has around 33,000 well


trained employees in 75 countries

•It has a wide global footprint with a


presence in almost190 countries

Opportunities Threats
• The anticipated regulatory approval of •Increasing public debt in European
Degludec in the US and Europe can countries is posing a threat to the
provide the comapny with an company
opportunity to further increase its share
in the Global Diabetes Drugs market •Stringent healthcare regulations can
delay the introduction of new drugs in
• With the anticipated regulatory the market. This will affect the company
approval of Degludec, the company
can become the key beneficiary if •Negative consequences of healthcare
investors believe that there is strong reforms in major markets can greatly
potential in emerging markets hamper the growth of the company

•The increasing prevalence of diabetes •Amylin Pharmaceuticals' new anti-


due to increasing urbanization will drive diabetes drug, Bydureon, can pose a
the sales of the diabetes drugs of the long-term threat to the company's best
company selling drug Victoza

•Generic insulin competition can pose a


big threat to the company in the near
future

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 31
14.2 Merck & Co., Inc.

Business Overview
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines,
biologic therapies, and animal health and consumer care products. The company was founded
in 1891 and it is headquartered in Whitehouse Station, New Jersey, US. The company recorded
turnover of US$48.05 billion in 2011 and it employs approximately 86,000 employees.

The company provides human health pharmaceutical products such as therapeutic and
preventive agents for the treatment of human disorders in the areas of cardiovascular disorders,
diabetes, obesity, respiratory disease, immunology, infectious diseases, neurosciences,
ophthalmology, oncology, and endocrinology. It also offers vaccines, including preventive
pediatric, adolescent, and adult vaccines. In addition, the company discovers, develops,
manufactures, and markets antibiotics, anti-inflammatory products, vaccines, products for the
treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, and
fish. Furthermore, it manufactures and sells over-the-counter products including non-drowsy
antihistamines, treatment for occasional constipation, decongestant-free cold/flu medicine for
people with high blood pressure, nasal decongestant spray, and treatment for frequent
heartburn. Additionally, the company provides foot care products including topical antifungal
products and foot and sneaker wetness products. It also provides sun care products such as sun
care lotions, sprays, and dry oils.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 32

Company Details Description

Product Portfolio  Janumet, Janumet Xr, Januvia, Juvisync

Recent Product Launches  In November 2011, Merck launched NEXPLANON


(etonogestrel implant) 68 mg in the US.
 In October 2011, the FDA approved the company's
product Juvisync, a new treatment for type 2 diabetes
that combines the glucose-lowering medication
Sitagliptin with the cholesterol-lowering medication
Zocor.
 In August 2011, Zoely, an oral contraceptive from the
company, was granted marketing authorization by the
European Commission for use in women to prevent
pregnancy.
 In May 2011, the FDA approved Victrelis, the company’s
innovative oral medicine for the treatment of chronic
hepatitis C.

Key Highlights  In March 2011, Merck received the 2011 ENERGY


STAR sustained excellence award from the US
Environmental Protection Agency (EPA).

Key Partnerships  In September 2011, Merck partnered with Susan G.


Komen for the treatment of cervical and breast
cancer and also to address cancer needs in developing
nations.

Key Mergers and Acquisitions  In May 2011, Merck completed the acquisition of Inspire
Pharmaceuticals Inc.
 In December 2010, the company acquired all of the
outstanding stocks of SmartCells, Inc.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 33
SWOT Analysis

Strengths Weaknesses
• Merck has robust in-house research • Integration efforts with Schering-Plough
capabilities, which make it a leader in involve plans to close or sell certain
designing new medical products facilities worldwide. This may result in
delays or failure in realizing all of its
•The company has a diversified product anticipated synergies
portfolio in the Pharmaceutical industry
•Marketing exclusivity and patent
•The company has a widespread protection for its key products in
geographic presence developed markets are about to expire

•The company has a limited liquidity


position compared to most of its
competitors

•The company is involved in numerous


lawsuits

•The company's expenses on R&D are


high

Opportunities Threats
• The merger with Schering-Plough •Uncertainty in global economic
Corp.will help it in cost savings and conditions could negatively impact the
revenue enhancement company’s sales and overall results

•The merger with Schering-Plough will •Continued exposure to patent expiries


help it to diversify its product portfolio and risk of generic competition to key
brands such as Singulair can pose a big
•Therapeutic diversification and threat to the company
expansion into the diabetes, oncology,
and infectious diseases segments will •The company is highly dependent on its
provide the company with many patent rights. If its patent rights are
opportunities for growth invalidated or circumvented, its business
would be adversely affected
•Diversification into the Biologics market
via acquisition of Abmaxis Inc. and •The company faces intense
GlycoFi Inc. will help the company to competition from lower-cost generic
increase its product portfolio and products
geographic presence

•Anticipated approval of Janumet XR for


diabetes can provide new opportunity
for growth in the diabetes field

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 34
14.3 Bristol-Myers Squibb Co.

Business Overview
Bristol-Myers Squibb Co. was formerly known as Bristol-Myers Company and changed its name to
Bristol-Myers Squibb Company in 1989. Bristol-Myers was founded in 1887 and is headquartered in
New York, US. The company generated revenue of US$21.2 billion in FY2011. Bristol-Myers
presently has 27,000 employees worldwide.

Bristol-Myers engages in the discovery, development, licensing, manufacturing, marketing,


distribution, and sale of biopharmaceutical products that help patients with serious diseases
worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart
attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy;
ELIQUIS to prevent and treat venous thromboembolic disorders and stroke prevention in atrial
fibrillation; ABILIFY, an agent for adult patients with schizophrenia, bipolar mania disorder, and
depressive disorder; and reyataz for the treatment of HIV. The company’s principal products also
include SUSTIVA for the treatment of HIV; Baraclude, an inhibitor of hepatitis B virus; erbitux to
target and block the epidermal growth factor receptor; Sprycel for the treatment of chronic
myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat moderate to
severe rheumatoid arthritis in adults; Nulojix to prevent solid organ transplant rejection; and
Onglyza for the treatment of type 2 diabetes. Its products under phase III clinical trials include
Brivanib to block the VEGF and FGF receptors; Dapagliflozin to treat diabetes; Necitumumab
and Elotuzumab for cancer treatment; and Daclatasvir for the treatment of hepatitis C virus. The
company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals,
clinics, government agencies, and pharmacies. It has strategic alliances with Pfizer Inc.,
AstraZeneca plc, Otsuka Pharmaceutical Co. Ltd., Eli Lilly, Gilead Sciences Inc., and Prosetta
Antiviral Inc., as well as strategic partnership with Tsinghua University.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 35

Company Details Description

Product Portfolio  Onglyza, Kombiglyze

Recent Product Launches  In December 2011, the FDA approved Onglyza for use
as a combination therapy with insulin in adult patients
with type 2 diabetes.
 In November 2011, the European Commission approved
Kombiglyze (known in the EU as Komboglyze) for the
treatment of type 2 diabetes.
 In November 2011, the European Commission approved
Onglyza for use as a combination therapy with insulin in
adult patients with type 2 diabetes.
 In May 2011, the company announced that the State
Food and Drug Administration approved Onglyza in
China.
 In 2010, Kombiglyze was launched in the US.

Key Highlights  In June 2011, Bristol-Myers Squibb Foundation awarded


$1.5 million in grants to various organizations to help
African American women fight type 2 diabetes.
 In March 2011, the FDA accepted a drug application for
investigational compound dapagliflozin for the
treatment of type 2 diabetes.

Key Partnerships  In September 2011, Bristol-Myers Squibb and Ambrx, Inc.


announced collaboration for novel biologics programs
in diabetes and heart failure.

Key Mergers and Acquisitions  In September 2011, Bristol-Myers Squibb acquired Amira
Pharmaceuticals, Inc. (Amira)
 In October 2010, BMS acquired 100 percent of the
outstanding shares of common stock of ZymoGenetics,
Inc.
 In September 2009, BMS acquired Medarex, Inc.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 36
SWOT Analysis

Strengths Weaknesses
• Bristol-Myers has an expansive alliance • The company failed to gain approvals
network for some new launches

•The company has strong financial ability •The company voluntarily recalled
to fuel growth options Viaspan in July, 2011

•The company has a broad product •Clopidogrel, one of the best selling
portfolio covering major therapeutic drugs of the company, is facing generic
areas competition since its patent expiry in
November, 2011

•The company is facing various product


liability lawsuits

Opportunities Threats
• The anticipated acquisition of Amylin •The company faces threats from the
Pharmaceuticals Inc. will help the regional players in emerging countries,
company to extend its product portfolio particularly in the APAC region
for diabetes
•The major portion of its revenue comes
•The anticipated acquisition of Inhibitex from the sales of hepatitis drugs in the
Inc. will help the company to increase US. Any adverse impact on the US
its total share in the Pharmaceutical economy will affect the growth of the
sector company

•In October 2010, the company • The emergence of new drugs is


acquired ZymoGenetics Inc., securing intensifying the competition for its drugs
an existing product as well as pipeline in various therapeutic markets
assets in various therapeutic areas. This
will help the company to increase its
global presence

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 37
14.4 Sanofi S.A.

Business Overview
Sanofi S.A. is a global pharmaceutical vendor engaged in the R&D, manufacture, and
marketing of pharmaceutical products. It is headquartered in Paris, France. The company was
formed as Sanofi-Aventis in 2004 by the merger of Aventis Pharma Ltd. and Sanofi-Synthelabo
Inc. It changed its name to Sanofi in May 2011. The company generated revenue of US$46.45
billion in FY2011. It has 101,575 employees worldwide.

Sanofi offers pharmaceutical products in the following areas: cardiovascular, central nervous
system, diabetes, internal medicine, oncology, and thrombosis. In terms of ethical
pharmaceutical sales, Sanofi-Aventis is the world's fourth largest pharmaceutical company and
Europe's largest pharmaceutical player. The group operates in more than 100 countries across
the EMEA region, the Americas, and the APAC region. The company's product portfolio includes
Lovenox/Clexane, Plavix/Iscover, Stilnox/Ambien/Ambien CR/Myslee, Taxotere, Eloxatin, Lantus,
Aprovel/Avapro/Karvea, Triatec/Tritace/Delix/Altace, Allegra/Telfast, Amaryl/Amarel/Solosa,
Xatral, Actonel, Depakine, and Nasacort. It also offers pharmaceutical products in consumer
healthcare and prescription drugs, including generics. The company offers vaccines in five
areas: influenza vaccines, pediatric combination vaccines, adult and adolescent booster
vaccines, meningitis vaccines, and travel and endemic vaccines.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 38

Company Details Description

Product Portfolio  Lantus, Apidra, Insuman, Amaryl/Amarel

Recent Product Launches  In 2011, the company launched BGStar and iBGStar
(blood glucose monitors) in several European markets.

Key Highlights  In December 2011, Sanofi announced the results of


meta-analysis on the possible relationship between
diabetes and the risk of cancer at the World Congress
of Diabetes. This meta-analysis showed no increased risk
for patients treated with Lantus.
 In December 2011, Sanofi announced positive results for
Lyxumia, a daily injection used in combination with
Lantus (Insulin glargine) in type 2 diabetes.
 In May 2011, Sanofi announced the support for the
"China Initiative for Diabetes Excellence", which is a
public-private partnership for the development of an
integrated model for diabetes management in China.
 In April 2010, Sanofi announced the positive Phase III
results of GetGoal lixisenatide (AVE0010).

Key Partnerships  In July 2010, Sanofi and the Juvenile Diabetes Research
Foundation signed a unique partnership to develop new
treatments for type 1 diabetes.
 In June 2010, Sanofi and Metabolex Inc. signed a global
licensing agreement on MBX-2982, an agonist of GPR119
receptor, for the treatment of type 2 diabetes.
 In April 2010, Sanofi and CureDM GroupHoldings, LLC,
signed a global licensing agreement for a new human
peptide, Pancreate, for use in patients with type 1 and
type 2 diabetes.

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 39
SWOT Analysis

Strengths Weaknesses
• Its revenue mainly relies on a few
•Sanofi has a strong global presence blockbuster products such as Ovenex
and Plavix
•The company owns a number of
patents on various high selling drugs •Its inability to withstand strong generic
worldwide competition has forced the company to
lay off some of its employees
•It has a rich R&D culture with almost
8,000 research personnel backing its
research activities

•Acquisition of Genzyme Corp. helped


the company in diversifying its product
portfolio along with expertise in ceratin
research fields

•The company offers comprehensive


care, covering both diagnosis and
patient services in terms of diabetic
care

Opportunities Threats
• Through various acquisitions •Growing generic competition can
undertaken, the company can expand cause price erosion of its existing drugs
its business to generics and consumer
health products. It can also strengthen •The company is facing patent
its R&D pipeline and product lines expiration of most of its best selling drugs

•The company has 15 major biologic •Counterfeit versions of the company's


drug components at different stages of injectable products pose a threat to its
drug development. This is expected to revenue
provide strong growth opportunity to
the company

•Its strong presence in emerging markets


will provide it with better opportunities
for growth in future

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 40
____________________________________________END_____________________________________________

Thank you for purchasing this report. As a valuable customer, can you please click here to give
us your feedback on this report?

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
Global Diabetes Drugs Market 41

15. Other Reports in this Series


Global Ventilation Systems and Accessories Market 2011–2015

Global Blood Glucose Monitoring Device Market 2011–2015

Global Dialysis Market 2011–2015

Global Active Pharmaceutical Ingredients Market 2011–2015

Global In Vitro Diagnostics Market 2011–2015

Global Blood Glucose Test Strips Market 2011–2015

Global Enzyme Inhibitors Market 2011–2015

Global Medical Disposable Market 2011–2015

Global Pneumococcal Vaccine Market 2011–2015

Medical Transcription Market in North America 2011–2015

Computed Radiography and Digital Radiography Market in Europe 2011–2015

Global Hepatitis Drugs Market 2011–2015

Global Drug-eluting Stents Market 2011–2015

Global Laparotomy Sponge Market 2011–2015

Global Digital X-ray Systems Market 2011–2015

Global Capnography Market 2011–2015

Global Tuberculosis Drugs Market 2011–2015

Global Dental Devices Market 2011–2015

Global Drugs of Abuse Testing Market 2011–2015

Global Wound Care Market 2011–2015

Global Laparoscopic Devices Market 2011–2015

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.
2011–2015 Global Diabetes Drugs Market

DISCLAIMER
This report has been prepared from sources and data that we believe to be
reliable, but we make no representation as to its accuracy or completeness. Any
decision or action taken by the recipient based on this report shall be solely and
entirely at the risk of the recipient. Opinions and information provided are made
as at the date of the report issue and are subject to change without notice.

All trademarks and copyrights remain the sole ownership of their rightful
owners/licensees. In no event shall Infiniti Research have any liability to any party
for special, incidental, tort, or consequential damages arising out of or in
connection with this report, even if Infiniti Research has been advised of the
possibility of such damages.

Copyright ©2012 Infiniti Research Limited. All Rights Reserved.

Reproduction without written permission is completely forbidden.

ABOUT TECHNAVIO INSIGHTS


TechNavio Insights is a customized set of reports based on the TechNavio
platform. It builds on the intelligence available within TechNavio and leverages
the custom research experience of our researchers.

TechNavio is built on years of experience of Infiniti Research in deep dive custom


research and consulting for over 30 Fortune 500 companies and numerous large
and medium-sized companies in the technology space.

For more information about TechNavio, please visit www.technavio.com

EMISPDF in-pwc001 from 42.110.128.177 on 2018-01-31 18:28:04 GMT. DownloadPDF.


2011–2015 Global Diabetes Drugs Market
Downloaded by in-pwc001 from 42.110.128.177 at 2018-01-31 18:28:04 GMT. EMIS. Unauthorized Distribution Prohibited.

Potrebbero piacerti anche